Related Experiment Video
Updated: May 21, 2025
07:15
An In Vitro Batch-culture Model to Estimate the Effects of Interventional Regimens on Human Fecal Microbiota
Published on: July 31, 2019
9.5K
Xylooligosaccharides mediated gut microbiome modulation: prebiotics to postbiotics
Vishal Kumar1, Ashutosh Bahuguna1, Subhash Kumar1,2
1Department of Food Science and Technology, Yeungnam University, Gyeongsan, Gyeongsangbuk-do, Republic of Korea.
Critical Reviews in Biotechnology
|March 18, 2025
Summary
Xylooligosaccharides (XOS) are beneficial prebiotics that promote gut health and can be produced affordably from agricultural waste. They offer potential in nutraceuticals for metabolic health, immune support, and cancer prevention.
Area of Science:
- Nutritional Science
- Microbiology
- Biotechnology
Background:
- Growing interest in nutraceuticals over pharmaceuticals for health management.
- Prebiotics, particularly xylooligosaccharides (XOS), are gaining attention for their health benefits.
- XOS are derived from renewable agricultural waste, making them economically viable.
Purpose of the Study:
- To review gut microbiome modulation by XOS.
- To explore XOS's health-promoting mechanisms, including immunomodulation and anticancer effects.
- To discuss the potential of XOS in nutraceutical applications, including synbiotics.
Main Methods:
- Review of in vivo, in vitro, and clinical studies on XOS.
- Analysis of XOS's impact on gut microbiota composition and function.
- Examination of XOS's role in producing beneficial postbiotics.
Main Results:
- XOS effectively stimulate beneficial gut microbiota growth.
- XOS consumption benefits individuals with metabolic abnormalities.
- XOS exhibit immunomodulatory and anticancer properties.
Conclusions:
- XOS are potent modulators of the gut microbiome, leading to health benefits.
- XOS offer a sustainable and cost-effective prebiotic option for the food and pharmaceutical industries.
- XOS-based synbiotics present a promising nutraceutical strategy for enhancing human health.
More Related Videos
Related Concept Videos
01:50What is Monogastric Digestion?
70.3K
The human body contains a monogastric digestive system. In a monogastric digestive system, the stomach only contains one chamber in which it digests food. Several other animal species also have monogastric digestive systems, including pigs, horses, dogs, and birds. This chapter, however, focuses on the human digestive system.
70.3K
01:21Drugs for Treatment of Constipation-Predominant IBS
124
Pharmacological therapies for IBS-C are designed to alleviate abdominal discomfort and enhance bowel function. In patients with IBS-C, fiber supplements may help soften stools and decrease straining, but may also lead to increased gas production and bloating. Osmotic laxatives like milk of magnesia are frequently used to soften stools and increase stool frequency in IBS-C patients. In addition, two drugs approved for use in severe IBS-C adult cases are linaclotide (Linzess) and lubiprostone...
124
01:29Bacterial Flora of the Large Intestine
369
The gut microbiome is formed by a vast and diverse community of bacteria that colonizes our large intestine. These bacteria start residing in the gut from birth and continue diversifying throughout life, influenced by factors such as diet, lifestyle, and stress. The gut bacterial community also includes bacteria from food and those that enter the colon through the anus.
The normal gut flora of the colon plays a critical role in generating essential vitamins such as vitamins K, B5, and B7.
The normal gut flora of the colon plays a critical role in generating essential vitamins such as vitamins K, B5, and B7.
369
01:20Drugs Affecting GI Tract Motility: Other Laxatives
141
Laxatives are primarily used to alleviate constipation, a common gastrointestinal disorder characterized by infrequent bowel movements and difficulty passing stools. They work by various mechanisms to increase the volume or frequency of bowel movements. The primary modes of action of laxatives include increasing stool bulk, softening the stool, stimulating intestinal motility, and osmotically drawing water into the intestines.
Osmotic or saline laxatives, like magnesium hydroxide or milk of...
Osmotic or saline laxatives, like magnesium hydroxide or milk of...
141
01:17Drugs for Treatment of Diarrhea-Predominant IBS
131
Diarrhea-predominant irritable bowel syndrome (IBS-D) is a subtype of IBS characterized primarily by frequent, loose, or watery stools, abdominal pain, and abdominal discomfort. Therapeutic approaches to managing IBS-D include dietary changes, stress management techniques, and pharmaceutical interventions.
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
131
01:19Oral Hypoglycemic Agents: α-Glucosidase Inhibitors
139
α-glucosidase inhibitors, including acarbose (Precose), miglitol (Glyset), and voglibose (Voglib) (primarily available in Asia), are drugs that control blood sugar levels by delaying the digestion of starch and disaccharides. They achieve this by inhibiting α-glucosidase enzymes in the intestine, which slow the absorption of carbohydrates in the intestine, which in turn leads to a prolonged release of the glucoregulatory hormone GLP-1 from intestinal L-cells.
Acarbose and miglitol are...
Acarbose and miglitol are...
139